newsfilter
← Earnings
Earnings Releases·

LENZ Therapeutics — Third Quarter 2026 Earnings Summary

LENZ Therapeutics reported third-quarter 2026 product sales of $2.6 million, representing a 50% increase over the prior quarter driven by telehealth adoption and expanded consumer awareness. The company announced a strategic reorganization effective in the fourth quarter to prioritize consumer marketing and reduce projected 2027 operating expenses by over 50%. Concurrently, CEO Eef Schimmelpennink will transition from his role on December 1, 2026, with Chief Financial Officer Dan Chevallard appointed as Interim President and CEO. The company's cash position stood at $197.3 million as of September 30, 2026, while net losses for the quarter and nine-month period totaled $31.0 million and $104.4 million, respectively.

Company
LENZ THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology